Key words
Hypericum perforatum
- Clusiaceae - stress - dexamethasone - biomarker - gene expression - FKBP5
Introduction
The flowering herb of Hypericum perforatum L. (Clusiaceae), commonly referred to as St. Johnʼs wort (SJW), is used in many countries
for the treatment of mild to moderate forms of depression (for review see [1]). Several bioactive compounds have been detected in the plant extract, and the pharmacological
activity has been reviewed previously [1]. It has been documented that the antidepressant activity of Hypericum extracts can be attributed to the phloroglucinol derivative hyperforin, to the naphthodianthrone
hypericin, and to several flavonoids. Dysregulation of the hypothalamic-pituitary-adrenal
(HPA) axis plays an important role in the pathogenesis of depression [2]. It has been shown that chronic exposure to environmental stress contributes to
the development of depression. The HPA axis, as one of the key endocrine adaptors
against stressors, is one of the major systems involved in physiological stress response.
The effects of SJW and single compounds on the expression of genes that are potentially
involved in the regulation of stress-induced aberrations of HPA axis function have
been reported earlier by our group using in vivo models [3], [4]. To further investigate the action mechanism(s) of SJW (commercial preparation STW3-VI)
and its active compounds hyperforin and miquelianin, we established an in vitro stress model using the human neuroblastoma cell line SH-SY5Y since they are widely
employed in neuropharmacology and are considered a suitable model for investigating
the cellular and molecular basis of depression [5]. Using these cells, we assessed the expression of genes using real-time qRT-PCR
with and without treatment of dexamethasone (DEX). Cells were treated with the glucocorticoid
receptor (GR) agonist DEX to mimic stress conditions [5]. The selected panel of genes comprises receptors and regulators of neuronal function,
which had been previously used in other cell types to investigate effects of neurotropic
substances [6], [7]. Glucocorticoids affect cellular and molecular events in brains by modulating the
expression of many genes during stress. It was therefore of interest to investigate
the effects of STW3-VI, hyperforin, miquelianin ([Fig. 1]), and the selective serotonin-reuptake inhibitor (SSRI) citalopram on gene expression
alone and in combination with DEX. Quantitative real-time PCR was used to determine
the expression of FKBP5 (FK506 binding protein 51), CREB (cAMP responsive element
binding protein), GRIK4 (glutamate ionotropic receptor kainate type subunit 4), VEGF
(vascular endothelial growth factor), NET (norepinephrine transporter), and ARRB (β-arrestins), which have been shown to be meaningful biomarkers in the treatment response
for depression [8].
Fig. 1 Chemical structures of hyperforin and miquelianin.
Results
DEX alone or in combination with the different substances did not affect cell viability
in SH-SY5Y cells at 6 h or 48 h of co-incubation ([Fig. 2 A – E]). The time points were chosen based on the study of Donnici et al. [9], who showed time-dependent differences in the expression of BDNF (brain-derived
neuropathic factor) after treatment of various antidepressant.
Fig. 2 A, B Effect of DEX (1, 10, and 100 µM) on cell viability of SH-SY5Y cells (ATP assay).
The cells were cultured with DEX for 6 and 48 h. C, D The effect of citalopram (0.1 – 10 µM), miquelianin (0.1 – 10 µM), hyperforin (0.1 – 1 µM),
and STW3-VI (10 – 50 µg/mL) after 6 and 48 h on cell viability in SH-SY5Y cells. E, F The cells were cotreated with citalopram, miquelianin, hyperforin, and STW3-VI for
6 and 48 h, after which the ATP assay was performed. Experiments were performed in
triplicate and results are shown as mean ± SEM from three independent experiments
(n = 9). *** p < 0.001 vs. control treated cells.
For the initial co-incubation experiments, DEX was used in concentration of 1 – 100 µM,
as reported in the literature [10]. The effects on cell viability are shown in [Fig. 2 A, B]. The ATP assay revealed that DEX at concentrations of 1, 10, and 100 µM given for
6 and 48 h ([Fig. 2 A, B]) was not toxic for SH-SY5Y cells. Cell viability slightly decreased after 48 h for
100 µM DEX (82% viability).
To evaluate whether the citalopram, hyperforin, miquelianin, or STW3-VI had any toxic
effects, the viability of SH-SY5Y cells after exposure to the various compounds for
6 or 48 h alone ([Fig. 2 C, D]) or in combination with DEX (10 µM) ([Fig. 2 E, F]) was determined using the ATP assay. As shown in [Fig. 2 C], citalopram (0.1 – 10 µM), miquelianin (0.1 – 10 µM), hyperforin (0.1 – 1 µM), or
STW3-VI (10 – 50 µg/mL) did not induce any significant changes in cell viability after
6 h. However, after 48 h of exposure, STW3-VI at a concentration of 50 µg/mL significantly
reduced cells viability as shown in [Fig. 2 D]. Based on these experiments, for the following co-incubation treatments with DEX,
citalopram and miquelianin were used in concentrations of 10 µM, hyperforin in 1 µM,
and STW3-VI in 20 µg/mL, respectively.
As shown in [Fig. 3], FKBP5 was upregulated after 6 h of DEX treatment (1.4-fold) ([Fig. 3 A]), but an even stronger increase in mRNA expression was observed after 48 h (2.0-fold)
([Fig. 3 B]). While after 6 h of co-incubation only STW3-VI could reverse the DEX-induced increase
in FKBP5 expression, after 48 h citalopram, miquelianin and hyperforin abolished the
glucocorticoid-induced increase in FKBP5 mRNA expression.
Fig. 3 Fold changes occurring in FKBP5, CREB, GRIK4, VEGF, NET, and ARRB2 expression after
(A) 6 h co-incubation with DEX (10 µM) or (B) 48 h co-incubation with DEX (10 µM). Citalopram and miquelianin were used in a concentration
of 10 µM, hyperforin in a concentration of 1 µM, and STW3-VI at 20 µg/mL. Data represent
the mean of three independent experiments. The bars represent an increased (> 1) or
decreased (< 1) change in comparison to the unstressed control (for DEX) or to the
DEX-treated control (for treatments). The absolute numbers and corresponding confidence
intervals are presented in [Table 1].
Table 1 Fold expressions of FKBP5, CREB, GRIJ4, VEGF, NET, and ARRB2 after 6 h co-incubation
with DEX (10 µM) or 48 h co-incubation with DEX (10 µM). Citalopram (10 µM), miquelianin
(10 µM), (1 µM), and STW3-VI (20 µg/mL) were co-incubated with DEX for the designated
time intervals. The numbers represent an increased (> 1) or decreased (< 1) change
in comparison to the unstressed control (for DEX) or to the DEX-treated control (for
treatments). Data are shown as mean and confidence interval of three independent experiments.
|
Symbol
|
Control + DEX
|
Citalopram + DEX
|
Miquelianin + DEX
|
Hyperforin + DEX
|
STW3-VI +DEX
|
|
6 h + DEX
|
|
FKBP5
|
1.41 (1.28 – 1.55)
|
1.28 (1.23 – 1.31)
|
1.19 (1.08 – 1.30)
|
1.27 (1.15 – 1.31)
|
0.92 (0.88 – 0.95)
|
|
CREB
|
0.80 (0.78 – 0.81)
|
0.72 (0.59 – 0.88)
|
1.14 (1.08 – 1.20)
|
1.15 (1.04 – 1.27)
|
1.10 (1.08 – 1.21)
|
|
GRIK4
|
0.58 (0.50 – 0.67)
|
1.45 (1.23 – 1.70)
|
1.44 (1.22 – 1.70)
|
1.61 (1.55 – 1.68)
|
1.48 (1.15 – 1.89)
|
|
VEGF
|
0.82 (0.76 – 0.87)
|
1.40 (1.14 – 1.72)
|
1.43 (1.28 – 1.59)
|
1.53 (1.46 – 1.59)
|
1.14 (1.05 – 1.23)
|
|
NET
|
1.35 (1.31 – 1.39)
|
0.84 (0.76 – 0.92)
|
0.82 (0.74 – 0.91)
|
0.98 (0.97 – 0.99)
|
0.92 (0.86 – 0.97)
|
|
ARRB2
|
0.39 (0.37 – 0.40)
|
0.57 (0.56 – 0.58)
|
0.76 (0.67 – 0.86)
|
0.96 (0.95 – 0.97)
|
0.77 (0.67 – 0.87)
|
|
48 h + DEX
|
|
FKBP5
|
2.05 (1.82 – 2.31)
|
0.67 (0.56 – 0.80)
|
0.82 (0.77 – 0.87)
|
0.74 (0.65 – 0.83)
|
0.78 (0.69 – 0.87)
|
|
CREB
|
0.78 (0.74 – 0.82)
|
0.94 (0.84 – 1.03)
|
0.86 (0.79 – 0.94)
|
1.61 (1.53 – 1.84)
|
1.28 (0.17 – 1.39)
|
|
GRIK4
|
0.77 (0.70 – 0.84)
|
0.82 (0.77 – 0.86)
|
0.71 (0.63 – 0.80)
|
1.09 (0.80 – 1.47)
|
0.64 (0.49 – 0.83)
|
|
VEGF
|
0.54 (0.49 – 0.60)
|
0.85 (0.82 – 0.86)
|
0.98 (0.91 – 1.04)
|
0.71 (0.62 – 0.80)
|
1.49 (1.23 – 1.80)
|
|
NET
|
1.25 (1.20 – 1.30)
|
0.65 (0.63 – 0.67)
|
0.72 (0.63 – 0.82)
|
1.08 (1.07 – 1.09)
|
0.64 (0.52 – 0.76)
|
|
ARRB2
|
0.69 (0.59 – 0.79)
|
0.73 (0.71 – 0.75)
|
0.84 (0.80 – 0.88)
|
1.39 (1.35 – 1.42)
|
1.43 (1.42 – 1.66)
|
In the present study, a decrease in the gene expression of CREB was observed after
6 h and 48 h of co-incubation with DEX; however, the effect level remained the same.
After 6 h, only miquelianin, hyperforin, and STW3-VI abolished the DEX stress-induced
decrease in CREB expression. Co-incubation of cells with DEX and citalopram, miquelianin,
hyperforin, or STW3-VI for 48 h showed that only hyperforin and the Hypericum extract could increase CREB expression by 1.6-and 1.3-fold, respectively.
We found differing effects of citalopram, hyperforin, miquelianin, and STW3-VI on
GRIK4 expression in SH-SY5Y cells. Time-dependent effects were observed after co-incubation
with DEX. After 6 h, GRIK4 expression was markedly decreased after DEX treatment (0.58-fold),
while co-incubation of DEX with citalopram, miquelianin, hyperforin, and STW3-VI increased
GRIK4 mRNA expression by 1.4 – 1.6-fold, respectively ([Fig. 3 A]). However, after 48 h, DEX-treated cells still showed a decrease in GRIK4 expression,
but the effect was less pronounced than after 6 h ([Fig. 3 B]). The treatment effect with the various test compounds also seemed to be time-dependent
since after 48 h we did not observe a difference in fold expression compared to the
DEX-treated control. Only in cells that were cotreated with DEX and hyperforin did
a marginal increase in GRIK4 mRNA expression occur ([Fig. 3 B]).
In the present study, time- and treatment-dependent effects have been observed for
VEGF mRNA expression in SH-SY5Y cells. VEGF mRNA expression was decreased when cells
were exposed to DEX, the effect being time-dependent. The DEX-induced decrease was
more pronounced after 48 h (0.54-fold) than after 6 h (0.82-fold) ([Fig. 3 A, B]).
While after 6 h of co-incubation with DEX citalopram, miquelianin, hyperforin, and
STW3-VI increased VEGF mRNA expression by up to 1.5-fold (hyperforin), after 48 h,
only STW3-VI showed an increase in VEGF mRNA expression.
NET expression was increased after 6 h (1.35-fold) and 48 h (1.25-fold) after treatment
of the cells with DEX ([Fig. 3 A, B]). The stress-induced increase in NET mRNA expression was attenuated by antidepressant
treatment at both time points as displayed in [Fig. 3 A, B].
Treatment with DEX, mimicking stress conditions, caused a marked decrease in the expression
of ARRB2. The effect was time-dependent since it was more pronounced after 6 h (0.39-fold)
of incubation compared to 48 h (0.69-fold). However, the drug treatment effect also
was time-dependent. After 6 h of co-incubation with DEX, only hyperforin diminished
the stress-induced effect (0.96-fold), while after 48 h hyperforin (1.39-fold) and
STW3-VI (1.43-fold) could reverse the effect of DEX.
To confirm the results in mRNA expression levels of FKBP5 and VEGF, ELISA assays were
carried out. ELISA for FKPB5 and VEGF production were performed only after 48 h since
the gene expression experiments revealed that the effect is more pronounced after
a longer incubation time. As shown in [Fig. 4 A], FKPB5 production after treatment with DEX (10 µM) was increased after 48 h compared
to the untreated control group. Co-incubation with citalopram (10 µM), miquelianin
(10 µM), hyperforin (1 µM), and STW3-VI (20 µg/mL) diminished the glucocorticoid-induced
increase in FKBP5. Addition of DEX (10 µM) decreased VEGF secretion ([Fig. 4 B]) after a 48-h incubation. In the presence of citalopram (10 µM), miquelianin (10 µM),
and STW3-VI (20 µg/mL), the DEX-induced decrease in VEGF could be partly reversed.
However, cotreatment of DEX with hyperforin caused no changes in VEGF secretion after
48 h.
Fig. 4 Effects of citalopram (10 µM), miquelianin (10 µM), hyperforin (1 µM), and STW3-VI
(20 µg/mL) on FKBP5 (A) and VEGF levels (B) after 48 h of DEX (10 µM) induced stress. FKBP5 and VEGF secretion were quantified
by commercial ELISA kits. Results are expressed as mean ± SEM (n = 3). * p < 0.05,
** p < 0.01, *** p < 0.001 vs. DEX control group; ## p < 0.01 and ### p < 0.001 vs. untreated control group.
Discussion
Our current study provides new insights on the molecular mechanism of SJW and two
of its active compounds. To the best of our knowledge, no data are available yet on
the effect of SJW, miquelianin, and hyperforin on the expression of genes that have
been identified as promising biomarkers of antidepressant therapy [8]. We could demonstrate in our study that the gene expression pattern of FKBP5, CREB,
GRIK4, VEGF, NET, and ARRB2 in SH-SY5Y neuronal cells is time- and treatment-dependent.
It is also shown that hyperforin and miquelianin, two compounds that have been shown
to possess antidepressant activities, exert different effects on various genes.
It is well known that dysregulation of the HPA axis plays an important part in the
development and maintenance of depressive symptoms [2]. The GR is a cytosolic transcription factor activated by the stress hormone cortisol
[11]. The GR translocates to the cell nucleus after cortisol binding. The translocation
of GR is a complex process and involves diverse molecular chaperones and cochaperones
including the FK506 binding protein 51 (FKBP5) [12]. FKBP5 regulates cortisol levels by attenuating the negative feedback of glucocorticoids
on the HPA axis [12]. Upon activation of GR, FKBP5 mRNA is upregulated. Interestingly, several FKBP5
genetic variants have been identified, which have been linked with various stressors
(e.g., psychosocial stress) and diverse phenotypes ranging from depression, psychosis,
or post-traumatic stress disorders to cardiovascular disease or cancer, supporting
the hypothesis that FKBP5 is a stress-sensitive biomarker [13]. Increased FKBP5 mRNA and protein expression have been reported in postmortem frontal
cortex from individuals suffering from major depression [14]. These findings in humans were also found in animal models. Guidotti et al. [15], for example, found an increased expression of FKBP5 after chronic mild stress in
rodents, which was normalized by chronic antidepressant treatment.
In the present study, we could show that not only the SSRI citalopram but also the
SJW extract (STW3-VI) and its active compounds miquelianin and hyperforin were able
to abolish the stress-induced increase in FKBP5 mRNA expression. Effects of STW3-VI
on HPA axis regulation have been shown earlier by our group [3], and the present mechanistic in vitro data are in good correlation with our previous findings, confirming an involvement
of STW3-VI in HPA axis regulation.
CREB1 is a member of the leucine zipper family of DNA binding proteins and is under
the inhibitory control of several kinases including GSK3A (glycogen synthase kinase
3 alpha) [16]. Several studies have focused on the role of CREB1 in antidepressant response mechanism.
CREB1 is upregulated by chronic antidepressant treatment, and increasing CREB levels
in rodent models result in antidepressant-like behaviors. Patients taking an antidepressant
at the time of death showed an increased level of CREB [17], whereas those who were not medicated at the time of death showed decreased levels
of CREB in temporal cortex. In a recent study, Lee et al. [18] showed that CREB phosphorylation increased time-dependently in SH-SY5Y cells after
20 µM tianeptine (SSRI) treatment, although the mRNA expression of CREB remained unchanged.
In another study by Zheng et al. [19], the transcript abundance of CREB in PC12 cells was elevated upon hyperoside treatment.
The authors conclude that the possible cellular mechanisms of the hyperoside antidepressant-like
effect is related to an elevation of the expression of CREB. Miquelianin and hyperoside
are structurally related and only differ in the substituent in position 3 of the aglycone
quercetin (hyperoside = quercetin-3-O-galactoside; miquelianin = quercetin-3-O-glucuronide).
In our present study, we used miquelianin (quercetin-3-O-glucuronide) representing
the group of flavonoids in SJW because it has been shown in earlier studies that this
compound can cross the blood-brain barrier [20]. Miquelianin abolished the DEX-induced decrease in CREB, but the effect was time-dependent,
being more evident after 6 h than after 48 h.
Our data are also in good correlation with the study of Gibon et al. [21], who demonstrated that a 72-h hyperforin treatment enhanced the expression of CREB
in cultured cortical neurons. In our experiments, only STW3-VI and hyperforin could
counteract the DEX-induced decrease of CREB gene expression in SH-SY5Y cells after
48 h. In a previous study, Trofimiuk et al. [22] found that an SJW extract increased the levels of pCREB in the aged ratʼs hippocampus,
suggesting an increase of CREB levels contributes to the mechanism of action of this
medicinal plant. Comparable to hyperforin, STW3-VI counteracted the DEX-induced decrease
in CREB mRNA levels in the current study, although the effect was less pronounced
than for the phloroglucinol derivative. Our data further suggest that the activity
of STW3-VI cannot be explained by hyperforin and miquelianin alone, since both compounds
had partially opposite effects of CREB gene expression. The SSRI citalopram had no
effects after 6 h and could only slightly counteract the stress-induced decrease in
CREB mRNA expression after 48 h. It is possible that the effect of citalopram on CREB
mRNA expression is time-dependent; in the study of Lee et al. [18], CREB phosphorylation increased time-dependently after tianeptine treatment, being
more evident after 72 h of incubation than after 24 h.
Glutamate receptors are traditionally divided into the ionotropic, ion channel-associated
AMPA, NMDA and kainate receptors 5 (GRIK1 – 5), and the G protein-coupled metabotropic
receptors [23]. In the last decade, the glutamatergic theory of depression has gained growing interest,
as many studies have documented the important role played by the glutamatergic system
in the pathophysiology of depression and mechanism of action of antidepressants [24]. Glutamate levels were increased in patients with major depressive disorder by proton
magnetic resonance spectroscopy [25], suggesting enhanced glutamatergic transmission. Ionotropic glutamate receptors,
such as the GRIK4-encoded kainic acid-type subunit, are responsible for fast-acting
neurotransmission. A role for ionotropic glutamate receptors in antidepressant action
has been supported by studies in rodents in which chronic treatment with antidepressants,
including citalopram, resulted in a region-specific reduction in binding activity
of N-methyl-D-aspartate receptors and N-methyl-D-aspartate receptor subunits [26]. Interestingly, decreased expression of the highly related GRIK1 and/or GRIK5 genes
has been observed in postmortem brains of patients with major depression and bipolar
disorder [27], [28]. In neurons, the expression of GRIK4 receptors is downregulated by chronic mild
stress and restored with fluoxetine [29]. In our present experiments, GRIK mRNA expression in SH-SY5Y cells was downregulated
after DEX treatment, with the effect being more pronounced after 6 h than after 48 h
of co-incubation. The treatment effect with various antidepressants also seemed to
be time-dependent. After 6 h, citalopram, miquelianin, hyperforin, and STW3-VI could
counteract the stress-induced decrease in GRIK4 expression. However, after 48 h, only
hyperforin showed a minor effect while all other treatment remained on the DEX control
level. To our knowledge, this is the first study demonstrating that natural compounds
can reverse a stress-induced decrease in GRIK4 mRNA expression.
VEGF is an important signaling protein involved in vasculogenesis and angiogenesis
[30] but is also expressed in the brain and has neuroprotective and neurogenic effects
[31]. Several studies demonstrate that VEGF is induced by various classes of antidepressants,
such as specific serotonin and norepinephrine reuptake inhibitors that increase VEGF
mRNA and protein expression in several types of brain cells [31]. Furthermore, chronic stress exposure decreased [32] and antidepressant administration increased hippocampal VEGF [31]. Interestingly, only a few number of studies exist reporting an increase in VEGF
expression after treatment with natural products, mostly in the context of wound healing
[33], [34]. In a previous study, Tassone et al. [35] demonstrated that VEGF expression increased more than three-fold in DAOY medulloblastoma
cells when the cells were treated with hyperforin, which is comparable to our present
findings. To our knowledge, the current study is the first study demonstrating a decrease
in VEGF mRNA expression in neuroblastoma cells after incubation with DEX. The effect
was time-dependent, being more evident after 48 h. However, the antidepressant treatment
effect was also time-dependent. After 6 h of co-incubation with DEX, citalopram, miquelianin,
and hyperforin reversed the stress-induced decrease in VEGF expression while the SJW
extract had only moderate effects. A different picture occurred after 48 h, where
STW3-VI was the only treatment, which significantly counteracted the DEX effect. However,
the VEGF effects determined by real-time PCR were only partially confirmed by the
ELISA assay: a possible explanation is the strict specificity of the immuno-assay,
which detects only the 165-isoform of VEGF. The primers used for real-time PCR also
detected the most common RNA isoforms.
NET is responsible for the reuptake of norepinephrine and is mainly located on presynaptic
terminals of noradrenergic nerves throughout central and peripheral nervous systems
[36]. NET is a key protein in the regulation of noradrenergic transmission, and therefore,
its expression and function might be affected during stress. Studies reporting the
effects of acute stress on NET expression have shown inconsistent results and mRNA
levels of NET or NET binding sites in the locus coeruleus of rats and mice were reduced
[37], unchanged [38], or increased [39] by acute stress. Although these studies are controversial and incomplete, they suggest
that NET can be affected by stress. Glucocorticoids are the key hormones released
during stress and therefore may play an essential role in the pathophysiological regulation
of NET. So far, there are very few reports regarding the possible regulatory effects
of stress hormones on NET expression in vitro. Sun et al. [40] used SK-N-BE(2)C cells and PC12 cells, two cell lines that naturally express NET
proteins, to assess the regulatory effect of corticosterone on NET expression. The
authors demonstrated that there is a closer association between this hormone and the
in vitro expression and function of NET. The results of Sun et al. [40] after 48 h are in line with the findings of Zha et al. [41], who showed that exposure of neuroblastoma SK-N-BE(2)M17 cells to DEX significantly
increased NET mRNA and protein levels in a time- and dose-dependent manner. In our
experiments, NET mRNA levels were increased after DEX stress after 6 and 48 h, the
effect being more pronounced after 6 h. In an earlier study, Zavosh et al. [42] used the human neuroblastoma cell line SH-SY5Y to estimate NET mRNA expression following
incubation with desipramine for 24 or 72 h. The authors could show that mRNA levels
of NET were decreased by desipramine, with somewhat different time courses, showing
a reliable decrease of NET mRNA at 72 h. We also could demonstrate that antidepressant
treatment decreased NET in a time-dependent manner, since in our study the reduction
in NET mRNA levels after antidepressant treatment was more evident after 48 h of co-incubation
with DEX.
ARRB are proteins that are important for regulating signal transduction at G protein-coupled
receptors [43], and findings in various research models support a major role for ARRB in the pathophysiology
of mood disorders as well as in the mechanism of action of antidepressants [44]. It has been shown that ARRB protein and mRNA levels in mononuclear leucocytes of
untreated patients diagnosed with a major depressive episode were significantly lower
than those of healthy subjects [45]. Interestingly, the low ARRB levels were increased by antidepressant treatment [45]. It was shown previously that DEX enhanced the expression of ARRB1 and suppressed
the expression of ARRB2 in human lung adenocarcinoma cells (A549) [46].
In our present study, we found time-dependent effects on ARRB2 mRNA expression in
SH-SY5Y cells after DEX-induced stress, the downregulation being more evident after
6 h. However, a treatment effect was visible only after 48 h and only for hyperforin
and STW3-VI. To our knowledge, this is the first study reporting an effect of natural
compounds on the expression of ARRB.
In conclusion, in an in vitro model of stress we analyzed for the first time a panel of genes comprising receptors
and regulators of neuronal function, which have been associated with antidepressant
response in previous studies. Using the glucocorticoid-receptor agonist DEX to mimic
stress conditions, we were able to show the responsiveness of the selected genes under
these in vitro conditions. Pronounced effects were observed 48 h after DEX treatment. The effects
observed on FKBP5, CREB, GRIK4, VEGF, NET, and ARRB2 were in good correlation with
published data, suggesting that this in vitro model can be used to screen the responsiveness of antidepressants under stress conditions.
Similarities as well as differences between the standard antidepressant citalopram
and hyperforin, miquelianin, and STW3-VI were detected. While both citalopram and
STW3-VI reduced the expression of FKBP5, NET, and GRIK4 after 48 h, they exerted opposite
effects on CREB, VEGF, and ARRB2, citalopram reducing and STW3-VI increasing the expression
of those genes. Interestingly, the effects of STW3-VI could not be explained by hyperforin
or miquelianin alone, suggesting that STW3-VI appears to have several active components
that interact differently with various molecular targets. It is important to mention
that this study was performed in cells; therefore, direct extrapolation to brain effects
should thus be taken with due reservation. However, bearing in mind this limitation,
neuronal cell cultures can provide a convenient and reliable tool to unravel new mechanisms
of antidepressant action that need to be further verified in more complex experimental
models.
Material and Methods
Materials
Accutase solution, DEX (≥ 97%), DMSO, DMEM, horse serum, hyperforin (dicyclohexylammonium)
salt (≥ 98%), and citalopram hydrobromide (≥ 98%) were purchased from Sigma-Aldrich.
Miquelianin (≥ 95%) was obtained from Extrasynthese. CellTiter-Glo Luminescent Cell
Viability Assay, M – MLV reverse transcriptase, and M – MLV RT (5X) buffer were ordered
from Promega. Fetal bovine serum (FBS), GlutaMA (100X), Dulbeccoʼs phosphate-buffered
saline (DPBS) without Ca2+/Mg2+ and Penicillin/Streptomycin were purchased from Gibco. dNTP Mix (20 mM of each) was
obtained from Solis Biodyne. TaqMan Gene Expression Assay probes were bought from
Thermo Fisher Scientific. FastStart TaqMan Probe Master Mix (2X) was bought from Roche
Diagnostics.
SJW extract (STW3-VI) was kindly provided by Steigerwald Arzneimittelwerk GmbH (STW3-VI,
DER = 3 – 6 : 1, extraction solvent 80% EtOH, containing 0.16% hypericin, 1.2% hyperforin,
and 8% total flavonoids calculated as rutin; Lot Nr. 0100228602). The extract (voucher
specimen # STWE-IPT2016) was stored at − 80 °C.
Cell culture
The human neuroblastoma cell line SH-SY5Y was a gift of Prof. A. Eckert (Psychiatric
University Clinics, Basel, Switzerland). Cells were cultured in DMEM supplemented
with 10% (v/v) FBS, 5% (v/v) horse serum, 1% (v/v) GlutaMAX, 100 U/mL penicillin and
100 µg/mL streptomycin at 37 °C in a humidified atmosphere of 5% CO2. At 70 – 90% confluence, the cells were subcultured by disassociation with Accutase
a split ratio of 1 : 3 – 1 : 4. For experiments, cells of passage number 23 – 25 were
used.
Test substances
Test substances were dissolved in DMSO (citalopram hydrobromide 10 mM, miquelianin
10 mM, hyperforin dicyclohexylammonium salt 10 mM, DEX 10 mM, STW3-VI 200 mg/mL) and
stored in aliquots at − 80°C. For experiments, test substances were diluted with DMEM
supplemented with 1% (v/v) FBS, 1% (v/v) GlutaMAX, 100 U/mL penicillin, and 100 µg/mL
streptomycin to the final assay concentrations (citalopram and miquelianin 10 µM,
hyperforin 1 µM, and STW3-VI 20 µg/mL). The final DMSO concentration did not exceed
0.2%.
ATP assay
To determine cell viability, ATP levels were determined using the CellTiter-Glo luminescent
assay. One hundred microliters of the SH-SY5Y cell suspension was seeded into 96-well
plates (Corning) at a density of 25 000 cells/well, followed by an incubation period
of 24 h (37 °C, 5% CO2). Cells were treated with test substances in the presence or absence of DEX (1 – 100 µM)
for 6 h and 48 h, respectively. After the desired incubation time, 100 µL CellTiter-Glo
reagent was added to each well and shaken for 2 min on an orbital shaker at 200 rpm
(Edmund Bühler GmbH). After 10 min, 100 µL of each well was transferred to a white
96-well plate (Greiner Bio-One) and luminescence was measured at 470 nm (SpectraMax
L, Molecular Devices).
Real-time qRT-PCR
SH-SY5Y cells were seeded into 12-well plates (Corning) at a density of 250,000 cells/well,
followed by an incubation period of 24 h (37 °C, 5% CO2). Cells were treated with test substances in the presence or absence of DEX (10 µM)
for 6 h and 48 h, respectively. After the desired incubation time, cells were washed
with DPBS and total RNA was extracted using the RNeasy Mini Kit according to the manufacturerʼs
instructions. After extraction, RNA was treated with RNase-free DNase. Reverse transcription
was performed using the Biometra T3000 thermocycler. Five microliters RNA was incubated
for 5 min at 70 °C with 0.24 µg oligo-dT primers (Qiagen), followed by incubation
for 1 h at 37 °C with 200 U of M – MLV reverse transcriptase, 1× M – MLV reverse transcriptase
buffer, and 2 mM of each dNTP.
Real-time qPCR was performed using a Rotor-Gene Q PCR cycler (Qiagen) under the following
conditions: 10 min at 95 °C for initial denaturation, followed by 50 cycles of 15 s
at 95 °C and 1 min at 60 °C. Fluorescence was measured at 510 nm. qPCR reactions consisted
of 3 µL cDNA, or water as nontemplate control, 7.5 µL FastStart TaqMan Probe Master
Mix (2X), 0.75 µL of TaqMan Gene Expression Assay probes, and 3.75 µL of nuclease-free
water.
Primer and TaqMan probe sets for FKBP5 (Hs01561006_m1), CREB1 (Hs00231713_m1), GRIK4
(Hs00205979_m1), VEGF (Hs00900055_m1), ARRB2 (Hs01034132_m1), and β-actin (Hs01034132_m1) were obtained from Thermo Fisher.
All values were normalized to the expression of the reference gene β-actin.
ELISA assays
SH-SY5Y cells were seeded into 12-well plates (Corning) at a density of 250 000 cells/well,
followed by an incubation period of 24 h (37 °C, 5% CO2). Cells were treated with test substances in the presence of DEX (10 µM) for 48 h.
Test substances were additionally diluted in DMEM supplemented with 1% FBS and 1%
charcoal stripped FBS, respectively. Human VEGF ELISA (Thermo Fisher Scientific) and
FKBP5 ELISA (LifeSPan Biosciences) were performed according to the manufacturerʼs
instructions. Optical density was measured at 450 nm (microplate reader Spectramax
M2e, Molecular Devices). All ELISA assays were performed in triplicate on three independent
days (n = 3).
Statistical analysis
ATP and ELISA experiments were performed in triplicates; each experiment was repeated
at least three times (on different days). Data are shown as mean ± standard error
of the mean (SEM).
Further statistical analysis was carried out by one-way analysis of variance (ANOVA)
followed by Dunnettʼs multiple comparison test using the software package GraphPad
Prism (version 5.0, GraphPad Software Inc.). In all cases, differences were considered
significant if p < 0.05.
PCR experiments were executed in duplicates, a sample and one technical replicate;
all experiments were repeated at least four times (on different days). To determine
relative expression values, the −ΔΔCt method (Applied Biosystems) was used, where
triplicate threshold cycle (Ct) values for each sample were averaged and subtracted
from those derived from the housekeeping gene actin. The Ct difference for a calibrator
sample was subtracted from those of the test samples, and the resulting −ΔΔCt values
were raised to a power of two to determine normalized relative expression (2−ΔΔCt = fold expression). Based on this calculation, the corresponding control groups for
the 6 h and 48 h incubation time points were set to 1. Changes in fold expression
were then calculated either relative to the untreated control cells for DEX effects
or relative to the DEX treated cells for antidepressant treatment effects and were
defined as unchanged (= 1), increased (> 1), or decreased (< 1). All data are expressed
as mean and confidence interval, and all numbers are shown in [Table 1]. Data presentation was performed according to Chittur et al. [47].
